Acorah Software Products - Accounts Production 16.0.110 false true 28 February 2023 1 March 2022 false 1 March 2023 28 February 2024 28 February 2024 11832545 Mr Tabassam Zabier iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 11832545 2023-02-28 11832545 2024-02-28 11832545 2023-03-01 2024-02-28 11832545 frs-core:FurnitureFittings 2023-03-01 2024-02-28 11832545 frs-core:ShareCapital 2024-02-28 11832545 frs-core:RetainedEarningsAccumulatedLosses 2024-02-28 11832545 frs-bus:PrivateLimitedCompanyLtd 2023-03-01 2024-02-28 11832545 frs-bus:AbridgedAccounts 2023-03-01 2024-02-28 11832545 frs-bus:SmallEntities 2023-03-01 2024-02-28 11832545 frs-bus:AuditExempt-NoAccountantsReport 2023-03-01 2024-02-28 11832545 frs-bus:SmallCompaniesRegimeForAccounts 2023-03-01 2024-02-28 11832545 frs-bus:Director1 2023-03-01 2024-02-28 11832545 frs-countries:EnglandWales 2023-03-01 2024-02-28 11832545 2022-02-28 11832545 2023-02-28 11832545 2022-03-01 2023-02-28 11832545 frs-core:ShareCapital 2023-02-28 11832545 frs-core:RetainedEarningsAccumulatedLosses 2023-02-28
Registered number: 11832545
Zabier Pharma-Consulting Ltd
Unaudited ABRIDGED Financial Statements
For The Year Ended 28 February 2024
Contents
Page
Abridged Balance Sheet 1—2
Notes to the Abridged Financial Statements 3
Page 1
Abridged Balance Sheet
Registered number: 11832545
2024 2023
Notes £ £ £ £
FIXED ASSETS
Tangible Assets 4 3,457 4,067
3,457 4,067
CURRENT ASSETS
Debtors 2,466,941 2,656,557
Cash at bank and in hand 17,366 85,501
2,484,307 2,742,058
Creditors: Amounts Falling Due Within One Year (59,704 ) (150,954 )
NET CURRENT ASSETS (LIABILITIES) 2,424,603 2,591,104
TOTAL ASSETS LESS CURRENT LIABILITIES 2,428,060 2,595,171
NET ASSETS 2,428,060 2,595,171
CAPITAL AND RESERVES
Called up share capital 5 100 100
Profit and Loss Account 2,427,960 2,595,071
SHAREHOLDERS' FUNDS 2,428,060 2,595,171
Page 1
Page 2
For the year ending 28 February 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The member has not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.
All of the company's members have consented to the preparation of an Abridged Profit and Loss Account and an Abridged Balance Sheet for the year end 28 February 2024 in accordance with section 444(2A) of the Companies Act 2006.
On behalf of the board
Mr Tabassam Zabier
Director
29th November 2024
The notes on page 3 form part of these financial statements.
Page 2
Page 3
Notes to the Abridged Financial Statements
1. General Information
Zabier Pharma-Consulting Ltd is a private company, limited by shares, incorporated in England & Wales, registered number 11832545 . The registered office is Zabier Residence, Zabier Residence, Meins Road, Blackburn, BB2 6QQ.
2. Accounting Policies
2.1. Basis of Preparation of Financial Statements
The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.
2.2. Tangible Fixed Assets and Depreciation
Tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:
Fixtures & Fittings 15% Reducing Balance
3. Average Number of Employees
Average number of employees, including directors, during the year was: 2 (2023: 2)
2 2
4. Tangible Assets
Total
£
Cost
As at 1 March 2023 5,629
As at 28 February 2024 5,629
Depreciation
As at 1 March 2023 1,562
Provided during the period 610
As at 28 February 2024 2,172
Net Book Value
As at 28 February 2024 3,457
As at 1 March 2023 4,067
5. Share Capital
2024 2023
£ £
Allotted, Called up and fully paid 100 100
Page 3